Your session is about to expire
← Back to Search
Ultrasound Therapy
ExAblate for Essential Tremor (ET004 Trial)
N/A
Waitlist Available
Led By Nir Lipsman
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up treatment through 1 month
Awards & highlights
ET004 Trial Summary
This study is evaluating whether AF echo imaging is safe and feasible for use in the brain.
Eligible Conditions
- Essential Tremor
- Tremor
- Neurologic Symptoms
ET004 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ treatment through 1 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~treatment through 1 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of Device and Procedure related Adverse Events
ET004 Trial Design
1Treatment groups
Experimental Treatment
Group I: ExAblate 4000 SystemExperimental Treatment1 Intervention
ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ExAblate
2010
N/A
~130
Find a Location
Who is running the clinical trial?
InSightecLead Sponsor
89 Previous Clinical Trials
3,694 Total Patients Enrolled
12 Trials studying Essential Tremor
1,048 Patients Enrolled for Essential Tremor
Nir LipsmanPrincipal InvestigatorSunnybrook Health Science Centre
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger